CER Writing Strategy Guide for EU MDR 2017/745 Compliance

How to Write a Compliant Clinical Evaluation Report Under EU MDR 2017/745

Introduction

The Clinical Evaluation Report (CER) is the central regulatory document through which medical device manufacturers demonstrate that their device is safe, performs as intended, and provides clinical benefits that outweigh its risks. Under EU MDR 2017/745, the CER writing process has evolved into a rigorous, strategically planned activity that demands scientific precision, methodological transparency, and long-term lifecycle thinking.

For manufacturers seeking CE marking in the European Union, the CER is not a background document — it is one of the primary records reviewed by Notified Bodies during conformity assessments. A poorly written CER is one of the most common causes of audit findings, certification delays, and non-conformities. Getting the CER writing strategy right from the outset is essential.

This CER writing strategy guide outlines the key components of a compliant CER, the methodological standards required by EU MDR, best practices for structure and scientific tone, common pitfalls to avoid, and a practical step-by-step process to help manufacturers and clinical writers produce high-quality, MDR-compliant Clinical Evaluation Reports.

Overview: What Makes a CER Strategy-Driven Under EU MDR

A CER is a formal, documented assessment of clinical data relating to a medical device. Its primary objective is to demonstrate conformity with the General Safety and Performance Requirements (GSPR) of the MDR by providing systematic evidence of safety, performance, and clinical benefit. Unlike marketing materials, a CER must be objective, scientifically justified, and traceable to verifiable data sources.

Under EU MDR, clinical evaluation is not a one-time pre-market activity. It is a continuous process that must be updated throughout the device lifecycle using data generated from post-market surveillance (PMS) and Post-Market Clinical Follow-up (PMCF). A CER writing strategy therefore encompasses not only initial content development but also long-term maintenance, integration with risk management, and alignment with PMS and PMCF processes.

This guide covers all essential elements of an effective CER writing strategy: regulatory framework, core document structure, literature search methodology, clinical data appraisal, benefit-risk assessment, writing style, common pitfalls, and lifecycle maintenance obligations.

What Is a Clinical Evaluation Report (CER)?

A Clinical Evaluation Report is a structured regulatory document that compiles and analyses clinical data for a specific medical device to demonstrate its safety, clinical performance, and overall benefit-risk profile. It is required under Article 61 and Annex XIV of EU MDR 2017/745 for all medical devices seeking or maintaining CE marking in the European Union.

The CER is not a literature summary, a product brochure, or a historical archive. It is a living scientific document that systematically evaluates available clinical evidence — including published literature, clinical investigations, PMS and PMCF data, and real-world evidence — against the device’s intended purpose and the current State of the Art.

A well-written CER provides Notified Bodies and Competent Authorities with clear, transparent evidence that the manufacturer understands the clinical profile of their device, has rigorously assessed its safety and performance, and has established that benefits outweigh residual risks for the intended patient population.

Why CER Writing Strategy Matters for EU MDR Compliance

Under the earlier Medical Device Directive (MDD), a CER was often a straightforward literature summary with limited methodological rigour. The EU MDR has fundamentally changed this. Notified Bodies now assess CERs with significantly greater scrutiny, and the standards for clinical evidence, equivalence, literature review methodology, and benefit-risk assessment have been substantially raised.

A CER that lacks strategic planning typically presents symptoms that regulators quickly identify: unsupported clinical claims, weak or incomplete literature searches, inadequate critical appraisal, poor integration with risk management, or outdated evidence that no longer reflects current clinical practice. Each of these weaknesses can result in non-conformities, mandatory revisions, and certification delays.

Strategic CER Writing Reduces These Risks By:

Ensuring the clinical evidence base is comprehensive, current, and scientifically valid
Demonstrating methodological transparency that satisfies Notified Body audit expectations
Aligning clinical conclusions with risk management and post-market documentation
Enabling efficient lifecycle updates that maintain ongoing regulatory compliance
Supporting defensible benefit-risk assessments grounded in real-world evidence

What Do Official Regulations Say?

CERs are governed primarily by Article 61 and Annex XIV of EU MDR 2017/745. Article 61 establishes that clinical evaluation must be based on sufficient clinical data and must follow a defined, methodologically sound process. Annex XIV provides detailed requirements for the clinical evaluation plan, the literature review methodology, the appraisal process, and the documentation of conclusions.

MEDDEV 2.7/1 Revision 4 remains the principal guidance document for CER methodology. Although predating the MDR, it is widely applied by Notified Bodies and provides detailed standards for literature searches, study appraisal, equivalence assessment, and documentation. The Medical Device Coordination Group (MDCG) has supplemented this with guidance documents including MDCG 2020-1, MDCG 2020-5 on equivalence, and MDCG 2020-6 on sufficient clinical evidence.

Key Takeaways from Official Regulatory Guidance

Key Takeaways: CER Writing Requirements Under EU MDR

Clinical evaluation must be planned using a documented Clinical Evaluation Plan (CEP) before any data collection begins.
Literature reviews must be systematic, reproducible, and cover multiple databases with full documentation of methods.
Critical appraisal of all included clinical data is mandatory — results cannot simply be summarised.
Equivalence claims are heavily restricted under MDR; direct access to the equivalent device’s technical documentation is required.
The benefit-risk assessment must reference risk management documentation and be justified against current State of the Art.
PMS and PMCF data must be actively integrated into CER updates throughout the device lifecycle.
CER writing style must be objective, neutral, and evidence-based — promotional language is not acceptable.
The CER must align consistently with the Risk Management File, PMS reports, PMCF evaluation reports, and GSPR checklist.

EU MDR 2017/745 — Article 61 and Annex XIV

MEDDEV 2.7/1 Rev. 4 — Clinical Evaluation Guidelines

MDCG 2020-1 — Guidance on Clinical Evaluation

MDCG 2020-5 — Guidance on Clinical Evaluation: Equivalence

How to Write a Compliant CER: Step-by-Step Strategy

The following step-by-step breakdown provides a practical strategic framework for writing a compliant, high-quality CER under EU MDR. Each step is built around the regulatory requirements of EU MDR 2017/745, MEDDEV 2.7/1 Rev. 4, and relevant MDCG guidance.

Step-by-Step Breakdown

Step 1: Develop the Clinical Evaluation Plan (CEP)

The CEP is the mandatory roadmap for the entire CER. It must be written and approved before any clinical data is collected or reviewed. A well-structured CEP defines the scope and objectives of the evaluation, specifies the methods for literature search and data collection, sets the criteria for equivalence (if applicable), and identifies the clinical endpoints and acceptance criteria that will determine whether the evidence base is sufficient.

Define the device description, intended purpose, and target population with precision
Specify the clinical claims to be supported and the acceptance criteria for each
Document the literature search methodology, including databases, search terms, and inclusion/exclusion criteria
Identify all clinical data sources: literature, clinical investigations, PMS, PMCF, registries
Establish the update schedule aligned with device classification

Step 2: Establish the State of the Art (SOTA)

The SOTA section describes the current level of medical knowledge and clinical practice for the condition being treated or managed by the device. This sets the benchmark against which the device’s safety and performance will be evaluated throughout the CER.

Describe the medical condition, prevalence, and clinical burden
Identify current treatment options, clinical guidelines, and consensus documents
Document known risks, complications, and expected clinical outcomes
Identify alternative technologies and comparator devices

The SOTA is not about proving superiority. It is about demonstrating that the device performs at least as well as existing therapies while maintaining an acceptable safety profile relative to current standards of care.

Step 3: Conduct the Literature Search

The literature search is the foundation of the clinical data identification phase. Under EU MDR, it must be systematic, reproducible, and comprehensive. A poorly documented or incomplete literature search is one of the most common grounds for Notified Body non-conformities.

Search multiple databases: PubMed, Embase, Cochrane Library, and others relevant to the indication
Use both free-text terms and controlled vocabulary (MeSH, Emtree)
Apply Boolean operators to combine concepts and capture synonyms
Include grey literature: clinical trial registries, regulatory databases, conference proceedings
Document the complete search strategy — databases, search strings, date ranges, filters
Record the screening process using a PRISMA-style flow diagram

Step 4: Appraise and Analyse Clinical Data

Appraisal involves critically assessing the quality, relevance, and scientific validity of each clinical data source. This is not a summary exercise — it is a structured evaluation of study design, sample size, bias risk, endpoint relevance, and statistical robustness.

Apply structured appraisal tools (e.g., OCEBM levels of evidence, Cochrane risk-of-bias tool)
Assess study design, sample size, follow-up duration, and endpoint appropriateness
Identify and document limitations, biases, and confounding factors for each study
Weight evidence according to its quality and relevance to the specific device

Following appraisal, the analysis phase synthesises data across all sources to answer the core clinical evaluation questions: Is the device safe? Does it perform as intended? Is the benefit-risk profile acceptable? Data from multiple sources must be integrated rather than assessed in isolation.

Step 5: Write the Benefit-Risk Assessment

The benefit-risk assessment is the central clinical conclusion of the CER. It must demonstrate, based on the analysed evidence, that the clinical benefits of the device outweigh any residual risks after risk control measures are applied. It cannot stand alone — it must be directly linked to the Risk Management File.

Reference all identified risks from the risk management documentation
Quantify benefits using clinical performance data from the literature and clinical investigations
Justify the acceptability of residual risks in the context of current SOTA and alternative options
Incorporate PMS and PMCF findings to reflect real-world post-market experience
Ensure full consistency between the CER benefit-risk conclusions and the Risk Management File

Step 6: Structure the CER for Clarity and Audit-Readiness

A well-structured CER is easier to audit, easier to update, and more likely to satisfy Notified Body reviewers. Each section should flow logically from the one before it, with clear cross-references between clinical data, risk management, GSPR, and post-market documentation.

Follow a logical structure: device description, SOTA, CEP, literature review, data appraisal, data analysis, benefit-risk, PMS/PMCF linkage, conclusions
Use clear headings, consistent terminology, and precise language throughout
Avoid promotional language, unsubstantiated claims, or unsupported assertions
Include a comprehensive reference list with full citations for all sources
Cross-reference the GSPR checklist, Risk Management File, and PMS/PMCF reports explicitly

Common CER Writing Pitfalls to Avoid

Over-reliance on equivalence: MDR significantly restricts equivalence claims. Manufacturers must have contractual access to the equivalent device’s technical documentation — and must demonstrate equivalence on technical, biological, and clinical grounds simultaneously.
Inadequate literature search documentation: Notified Bodies expect full transparency on search methodology. Missing search strings, undocumented databases, or absent PRISMA diagrams are common non-conformity triggers.
Weak appraisal of clinical data: Simply listing study findings without assessing their quality, design, or limitations does not satisfy MDR requirements. Every included study must be critically evaluated.
Unsupported clinical claims: Every clinical claim in the CER must be traceable to a specific, appraised data source. Claims without evidence are non-conformities.
Insufficient PMS and PMCF integration: A CER that does not incorporate post-market evidence is not compliant under MDR. PMS and PMCF data must actively inform every CER update.
Misalignment with risk management: Contradictions between the CER benefit-risk conclusions and the Risk Management File are one of the most serious findings a Notified Body can make. Cross-functional consistency is essential.

Conclusion

Writing a compliant CER under EU MDR is no longer a straightforward literature exercise — it is a strategically planned, scientifically rigorous, and continuously maintained demonstration of a device’s safety, performance, and clinical benefit. A strong CER writing strategy combines a well-structured Clinical Evaluation Plan, comprehensive systematic literature review, rigorous critical appraisal, evidence-based benefit-risk assessment, and robust integration with risk management and post-market processes.

Manufacturers who invest in getting their CER writing strategy right from the outset are better positioned to achieve CE marking efficiently, pass Notified Body audits with confidence, and maintain regulatory compliance throughout the device lifecycle. The CER is not merely a compliance document — it is the most important clinical proof of a device’s value to patients and regulators alike.

CiteMed provides specialist CER writing services tailored to EU MDR requirements. From initial CEP development through full CER preparation, literature review, and lifecycle update support, our regulatory writing team brings the scientific rigour and MDR expertise your submissions require.

Frequently Asked Questions (FAQ)

What is the difference between a CER and a Clinical Evaluation Plan (CEP)?

The Clinical Evaluation Plan (CEP) is the pre-defined methodology document that sets out the scope, objectives, data sources, search strategy, and acceptance criteria for the clinical evaluation. The CER is the report that documents the execution of that plan — the actual data collected, appraised, and analysed, along with the conclusions drawn. The CEP comes first; the CER follows.

Can I use equivalence to write a CER under EU MDR?

Yes, but with significant restrictions. Under EU MDR, equivalence claims require that the manufacturer demonstrates equivalence on technical, biological, and clinical grounds simultaneously. For Class III and implantable devices, the manufacturer must also have contractual access to the equivalent device’s technical documentation. In practice, this makes equivalence difficult to establish for most manufacturers, and direct clinical data is generally preferred.

How long should a CER be?

There is no prescribed length for a CER under EU MDR. The appropriate length depends on the device’s classification, complexity, and clinical evidence base. A Class III implantable device with extensive clinical data may require a CER of several hundred pages. A lower-risk Class I device may require a significantly shorter document. The CER should be as long as necessary to comprehensively address all required content — no more, no less.

Who should write the CER?

Under EU MDR and MEDDEV 2.7/1 Rev. 4, the CER must be authored by individuals with appropriate expertise in clinical evaluation methodology, the medical field relevant to the device, and applicable regulatory requirements. Notified Bodies assess the qualifications and experience of CER authors. Many manufacturers engage specialist regulatory medical writers or clinical evaluation consultants to ensure their CERs meet the required scientific and regulatory standard.

What is the relationship between the CER and the GSPR checklist?

The General Safety and Performance Requirements (GSPR) checklist documents how each applicable GSPR is satisfied. The CER provides the clinical evidence that supports conformity with clinically relevant GSPRs — particularly those relating to safety, performance, and benefit-risk. The CER and GSPR checklist must be explicitly cross-referenced to demonstrate that clinical evidence supports each applicable clinical safety and performance requirement.

CER Writing Strategy Guide